Hailey Bieber and Justin Bieber Have a good time sixth Anniversary After Child

Hailey Bieber Shares Glimpse Into New Chapter After Giving Birth to Her and Justin Bieber’s Son Jack

Hailey Bieber and Justin Bieber are marking another milestone as a couple after baby, baby, baby.

The pair celebrated their six wedding anniversary Sept. 14, three weeks after the model gave birth to their first child, son Jack Blues Bieber.

Hailey, 27, shared romantic images to mark the occasion—pics of gold balloons bearing the word “Love you,” pink candles laid in between a bed of flowers and a blurry printed photo of her and Justin kissing placed on it.

“6 years,” she wrote on her Instagram Stories, adding a white heart and engagement ring emoji. “Love you baby.”

Hailey and Justin, 30, tied the knot at a New York City courthouse Sept. 14, 2018, two months after their got engaged during a trip to the Bahamas in July following a whirlwind summer rekindled romance. Just over one year later, the married again in a larger wedding ceremony in South Carolina in front of family and friends.

Invoice Maher Turns The Tables And Begins A Conspiracy Principle About Trump And Laura Loomer

Bill Maher gave Laura Loomer a dose of her conspiratorial mindset by asking if she is in an arranged relationship with Donald Trump to influence the 2024 election.

Maher said on HBO’s Real Time with Bill Maher:

Here’s my question, because she said, Laura Loomer said, Taylor Swift, she believes, is in an arranged relationship with Travis Kelsey to influence the 2024 election. I think maybe Laura Loomer’s in an arranged relationship to affect the election, because she’s very close to Trump

. She’s 31. Looks like his type.

We did an editorial here a few years ago. You’re remembering it already. It was basically, who’s Trump f*cking? Because I said, you know, it’s not nobody. He’s, he’s been a dog for too long. And, and it’s not Melania. I think we may have our, our answer this week. I think it might be Laura Loomer, I’m just saying.

Video:

I can’t believe this is actually happening.

Bill Maher is flipping the script on @LauraLoomer, claiming she is in an “arranged relationship” with Donald Trump.

But then he took it even further, suggesting Loomer is doing you know what with Trump.

“She’s 31, looks like his type… pic.twitter.com/WvHlDmnqDE

— The Vigilant Fox 🦊 (@VigilantFox) September 14, 2024

Republicans are pointing the finger at Loomer for playing into Trump’s conspiratorial mindset and manipulating the already unhinged ex-president.

Laura Loomer has been fighting with old enemy Rep. Marjorie Taylor Greene and told Sen. Lindsey Graham to come out of the closet. That was just this week so far.

Blaming Loomer for Trump’s nightmare debate is not accurate because Trump was also terrible in the first debate. Trump has never had a good debate in which he was able to stay on topic and connect with voters.

The bad debate wasn’t Laura Loomer’s fault, but Trump’s embrace of the debunked immigrants eating pets in Springfield, Ohio story has her fingerprints all over it.

Maher’s accurate point was that if Loomer wants to spread baseless conspiracies, she should be ready to have the same behavior thrown back at her.

To comment on this story, join us on Reddit.

Jason is the managing editor. He is also a White House Press Pool and a Congressional correspondent for PoliticusUSA. Jason has a Bachelor’s Degree in Political Science. His graduate work focused on public policy, with a specialization in social reform movements.

Awards and  Professional Memberships

Member of the Society of Professional Journalists and The American Political Science Association

Jason EasleyLatest posts by Jason Easley (see all)

Shein and Temu costs poised to rise after Biden de minimis proposal

A man walking past a logo of fast fashion e-commerce company Shein outside its office in Guangzhou in southern China’s Guangdong province. 

Jade Gao | Afp | Getty Images

The bottom of the barrel prices that have made Chinese-linked e-tailers Shein and Temu so popular with American consumers could soon rise if the Biden administration curtails their use of a trade law loophole.

The companies, known for their $5 T-shirts and $10 sweaters, could see prices rise by at least 20% if the so-called de minimis provision is changed, a spokesperson for the Republican majority of the House Select Committee on the Chinese Communist Party told CNBC. The committee made the estimate after launching investigations into Shein and Temu more than a year ago.

Neil Saunders, a retail analyst and the managing director of GlobalData, agreed the policy change would likely increase prices, but couldn’t say by how much. 

“If the de minimis exemption is removed, then the cost of products from marketplaces like Shein and Temu will rise. They will still be cheap marketplaces but they won’t have quite the competitive edge on price that they do now,” Saunders told CNBC in an email. “That may lose them some market share or slow their growth, but they will likely respond by pushing into some higher-priced items to balance out their propositions.”

On Friday morning, the Biden administration announced plans to bar overseas shipments of products that are subject to U.S.-China tariffs from being eligible for the de minimis exemption. 

An obscure tariff law loophole that’s been around since the 1930s, the exemption allows packages with a value of less than $800 to enter the United States without the shippers paying import duties and with less scrutiny than larger containers. 

The announcement comes after more than a year of scrutiny into the companies from lawmakers on both sides of the aisle and in particular, the House Select Committee on the CCP. 

Both Shein and Temu declined to tell CNBC if they will raise prices due the proposed changes. The companies also disputed that their low prices are driven by the de minimis exemption and said their business models allow them to offer their ultra-affordable rates.

A spokesperson for Shein noted that the company supports de minimis reform and was recently accepted into a voluntary, pilot program with U.S. Customs and Border Protection where it agreed to provide additional data about packages and shipments.

A risk to their competitive edge 

Over the last couple of years, the two companies have taken U.S. consumers by storm with their ultra-low prices and their ability to rapidly churn out trending styles far faster than competitors can. Shein is estimated to take in more than $30 billion in revenue annually, but it’s unclear what Temu’s sales are. Its parent company, PDD Holdings, saw $34.9 billion in revenue in fiscal 2023 — a 90% increase from the year ago period.

As the companies have become go-to shopping destinations, they’ve taken market share from rivals that cater to similar consumer segments, such as H&M, Zara, Target, Walmart and Amazon.

If Shein’s prices were to rise by 20%, it would put its assortment closer in line with those competitors, which could make it harder for it to compete.

For example, the average price of a dress on Shein was $28.51 as of June 1, according to data from Edited, a London-based research firm that analyzed the company’s pricing strategy and shared metrics with Reuters.

At the time, that price was well below the average cost for dresses at H&M and Zara, which were $40.97 and $79.69, respectively, according to Edited’s data. However, if costs were to rise by 20%, that would make the average dress price on Shein $34.21 – far closer to H&M’s average price.

There’s no guarantee prices would rise 20% if the Biden administration’s proposal takes effect. Still, taken together with the company’s long shipping times, a smaller discount relative to Shein’s rivals may lead some consumers to opt for retailers that are closer to home. 

“Ultimately, while reforming the de minimis rules makes for a fairer and more level playing field, like any tariff it will end up costing consumers more,” said Saunders. 

Scrutiny of a digital darling

Last year, the committee began investigating Shein and Temu for slave labor in their supply chains and zeroed in on their use of the de minimis exemption, claiming in a June 2023 report that both companies didn’t pay any import duties in 2022. Shein disputed that claim and said the company paid millions of import duties in 2022 and 2023. It has, however, acknowledged that cotton from banned regions has been found in its supply chain and said it’s working to rectify the issue. Temu didn’t respond to inquiries about slave labor in its supply chain.

“As the Select Committee’s investigation into Shein and Temu revealed, the majority of products from Shein and Temu fall under the de minimis exception. This allows them to dodge U.S. Customs and evade the scrutiny other retailers face. The U.S. must urgently curb these shipments and force these companies to correct their anemic compliance practices,” a spokesperson for the committee told CNBC.

The spokesperson added that “Congress must urgently make de minimis reform law.”

As scrutiny of Shein intensified, its hopes of pulling off a long awaited U.S. public offering dwindled. 

Lawmakers, eager to curtail the influence that Chinese-linked retailers were having on the U.S. economy and take steps they said would level the playing field for American companies, were unlikely to propose an outright ban of Shein and Temu, similar to what was done with social media company TikTok. 

Instead, numerous lawmakers called for the U.S. Securities and Exchange Commission to block Shein’s IPO and targeted the de minimis exemption as the best way to curtail the company’s growth. 

Now, more than a year into those efforts and Shein’s own sputtering charm offensive, its plans for a New York IPO are all but dead and it has turned to London in hopes of finding a friendlier reception. 

In June, CNBC reported that Shein had confidentially filed for a public listing in London as it faced backlash in the U.S. 

It’s unclear what impact the proposed de minimis changes will have on Shein’s IPO plans.

$1 billion in value cuts, 10 product launches deliberate

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. 

Plexi Images | GHI | UCG | Universal Images Group | Getty Images

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. 

The biotech company said it expects 10 new product approvals through 2027. But Moderna said it will also pause work on some products in its pipeline and scrap others, as it aims to “pace ourselves” in new research and development spending. 

The company aims to trim R&D spending to a range of $3.6 billion to $3.8 billion in 2027, down from an expected $4.8 billion at the end of this year, according to a release.

“You’re going to start seeing things come down because there are some studies that we are going to basically sunset and we’re not going to start,” Moderna CEO Stephane Bancel told CNBC, adding that the company is putting its latent product portfolio “on hold.” That refers to a category of viruses that linger inside patients for prolonged periods without causing any symptoms but can reactivate and cause serious health complications later in their lives. 

Still, shares of Moderna fell more than 15% on Thursday.

Leerink Partners analyst Mani Foroohar said in an email Thursday that the company’s updates “put to rest key elements of the bull thesis” for its stock and “reflect a worsening financial position.”

“R&D reductions are too far out chronologically to be credible from a management team that we think has proven serially unable to project the performance of their business,” Foroohar said.

In a research note Thursday, Jefferies analyst Michael Yee said that the bulk of the cost savings won’t be achieved until 2027, which “now delays profitability until 2028.”

Moderna said it plans to “break even” on an operating cash cost basis with $6 billion in revenue in 2028. The company previously said it expects to break even and return to growth in 2026.

The company expects 2025 revenue to come in at $2.5 billion to $3.5 billion. From 2026 to 2028, Moderna expects a compounded annual growth rate of more than 25% as new products launch. 

While Moderna expects some product approvals in 2025, the company is “not expecting meaningful revenue contributions until the year after,” Moderna CFO Jamey Mock told investors during the event.

Also on Thursday, Moderna announced positive late-stage trial results for its vaccine against respiratory syncytial virus in high-risk adults ages 18 to 59, with plans to file for approval for that age group this year. It also announced positive data on its experimental stand-alone flu shot for adults ages 65 and older. 

The company unveiled those updates during its annual research and development day investor event in New York on Thursday, which focuses on its product pipeline and long-term business updates. It comes around four months after U.S. regulators cleared Moderna’s RSV vaccine for seniors, its second commercially available product after its Covid vaccine. 

The company said it now has five respiratory shots with positive phase three results and expects to submit three of those jabs for approval this year. That includes Moderna’s combination shot targeting Covid and the flu, which it expects to file for approval in the U.S. this year, along with a new and more effective version of its Covid shot. 

Moderna also has five nonrespiratory products across cancer, latent viruses and rare diseases that could be approved by 2027, according to the company’s release. 

The company expects 2025 revenue to come in at $2.5 billion to $3.5 billion. From 2026 to 2028, Moderna expects a compounded annual growth rate of more than 25% as new products launch. 

“That’s really a remarkable achievement that the team has accomplished, leaving us with a lot of drugs that are working, which is why we need to pace ourselves in terms of R&D investment,” he told CNBC. 

What’s in Moderna’s pipeline?

Moderna presented new data on its RSV vaccine, mRESVIA, which is cleared in the U.S. and European Union for adults 60 and above. 

The company said the shot met all of the main efficacy goals in an ongoing phase three study on adults ages 18 to 59 who are at increased risk of getting severely sick from the virus. There were no safety concerns observed, Moderna added.

There are currently no RSV shots approved worldwide for younger, high-risk adults, such as those with weakened immune systems or underlying chronic conditions like asthma and diabetes. Moderna’s main rivals in the RSV space, Pfizer and GSK, are also seeking an expanded approval for the age group. 

Moderna CEO Stephane Bancel speaks at the grand opening of the company’s new headquarters outside Kendall Square.

David L. Ryan | Boston Globe | Getty Images

Bancel said the company plans to use a “priority review voucher” when it files for approval for people ages 18 to 59, which would reduce the amount of time it takes for the Food and Drug Administration to review the product to six months instead of 10 months. Moderna hopes the agency will clear mRESVIA for that age group in time for the RSV season in 2025. 

“It’s in the millions of people who could benefit. … We are also doing so just to be competitive in the marketplace because if you are a large retail pharmacy, you want your product to be available for all of your customers that show up,” Bancel said. 

But the company is also discontinuing development of its RSV vaccine for infants under 2 years old based on “emerging clinical data.” 

Moderna said its experimental stand-alone flu vaccine, mRNA-1010, produced a higher immune response against the virus compared with an existing flu shot in a recent phase three trial. The shot has also demonstrated “consistently acceptable safety and tolerability” across three late-stage trials, the company added.

Meanwhile, Moderna said it plans to move its shot against norovirus, a highly contagious stomach bug that causes vomiting and diarrhea, to a phase three trial “imminently.” Bancel said he believes the company could finish the study within a year and file for approval immediately after if the data is positive. 

More CNBC health coverage

“This could be a product that is two years away from launch, which is great because there’s nothing today to treat norovirus,” he said. “A lot of health-care professionals get infected by their patients.”

Moderna is also partnering with Merck to develop a personalized cancer vaccine, which is being studied in combination with Keytruda in patients with different forms of the disease. 

The companies are studying the shot in a phase three trial in patients with a deadly skin cancer and discussing an approval with regulators based on data from a mid-stage study on the jab.

But Moderna said the FDA has “not been supportive” of a so-called accelerated approval of the shot based on its existing data. That refers to an FDA designation that clears drugs faster if they fill an unmet medical need for serious conditions.

Bancel said, “we’re going to keep having discussions” with regulators, and “we’re also generating more data.”

— CNBC’s Angelica Peebles contributed to this report.

Don’t miss these insights from CNBC PRO

RFK Jr. again on Michigan poll, state Supreme Courtroom guidelines

Independent presidential candidate Robert F. Kennedy Jr. makes an announcement on the future of his campaign in Phoenix, Arizona, U.S. August 23, 2024. 

Thomas Machowicz | Reuters

Former independent presidential candidate Robert F. Kennedy Jr. will appear on the ballot in Michigan in November, the state’s Supreme Court ruled Monday, a decision that could boost the national candidacy of Democratic nominee Vice President Kamala Harris over GOP nominee former President Donald Trump.

The Supreme Court overturned the state’s Court of Appeals ruling Friday that had removed Kennedy from the state’s ballot against the wishes of Michigan Secretary of State Jocelyn Benson.

The majority decision by the high court on Monday was unsigned. But the text of the order implies that five of the seven justices who considered the case voted to keep Kennedy’s name on the ballot.

Harris leads Trump in Michigan polling averages regardless of the number of candidates. But her edge over Trump shrinks in a head-to-head matchup there.

Michigan’s 15 votes in the Electoral College — the entity that selects the winners of the U.S. presidential elections — is the second-highest number of any swing state, after Pennsylvania.

When Kennedy suspended his campaign on Aug. 23 and pledged to support Trump, he said he planned to remove his name from ballots in swing states — among them Michigan — where doing so would benefit Trump.

Kennedy, who was nominated by the Natural Law Party in Michigan, sued Benson after she rejected his request to remove his name.

Benson in her decision cited Michigan law, which says that minor party candidates who accept a nomination cannot withdraw from an election.

The majority in the Michigan Supreme Court, in its ruling Monday, wrote that Kennedy “has neither pointed to any source of law that prescribes and defines a duty to withdraw a candidate’s name from the ballot nor demonstrated his clear legal right to performance of this specific duty.”

“Thus, [Kennedy] has not shown an entitlement to this extraordinary relief,” the court majority said in its ruling.

The two justices who dissented from the ruling, Brian Zahra and David Viviano, wrote that by keeping Kennedy on Michigan’s ballot, “the Secretary of State is improperly and needlessly denying the electorate a choice between persons who are actual candidates willing to serve if elected.”

The dissenters in their last words underscored how significant the majority ruling could be to the outcome of the presidential race.

“We can only hope that the Secretary’s misguided action — now sanctioned with the imprimatur of this Court — will not have national implications,” they wrote.

Wisconsin and North Carolina also denied Kennedy’s request to remove his name from the ballots there.

As in Michigan, Kennedy sued officials in those two other states seeking to drop his name from their ballots.

A North Carolina appeals court on Friday sided with Kennedy, ordering the state’s election officials not to mail out ballots with his name as they had planned to do on that same day.

Paul Cox, the general counsel for North Carolina’s elections board, wrote in a memo to county election directors on Friday that “no decision has been made on whether this ruling will be appealed.”

A judge has yet to rule on Kennedy’s lawsuit in Wisconsin.

In Wisconsin, Harris’ polling lead over Trump shrinks when the race narrows to two candidates, according to RealClearPolling, and in North Carolina, Trump pulls ahead in that scenario.

Kennedy successfully withdrew his name from ballots in four other battleground states: Pennsylvania, Arizona, Nevada and Georgia.

But polling shows that in Georgia and Nevada, a two-way race may increase Harris’ chances, not Trump’s.

Nelson Peltz steps down as chair of Wendy’s board

Nelson Peltz speaking at the 2019 Delivering Alpha conference in New York on Sept. 19, 2019.

Adam Jeffery | CNBC

Nelson Peltz is stepping down as chair of Wendy’s, ending a 17-year reign at the fast-food chain.

Wendy’s said Friday that the change is effective immediately.

Peltz’s exit comes as low-income consumers eat out less, causing Wendy’s sales to slump. Shares of the burger chain have fallen more than 12% this year, dragging its market value down to $3.45 billion. Earlier this year, PepsiCo veteran Kirk Tanner stepped in as CEO and laid out plans to invest millions of dollars into updates to its mobile app and advertising to boost the business.

“In our view, [Peltz’s departure] opens the door for a new chapter under new Chairman Art Winkleblack & new CEO Kirk Tanner,” T.D. Cowen analyst Andrew Charles wrote in a note to clients Monday. Still, he maintained a “hold” rating for the stock, citing its lack of diversification compared with other restaurant peers.

Peltz will assume the title of chairman emeritus. He is stepping down to devote more time to his other board commitments and Trian Partners’ future activities, according to Wendy’s.

Peltz’s Trian Fund Management has a 10% stake in Wendy’s, making it the company’s second-largest shareholder behind Vanguard. Trian first invested in Wendy’s in 2005, when the fund was created. With Peltz’s departure, the firm holds two board seats at the fast-food company.

Trian said it was exploring a takeover of Wendy’s in 2022, but later decided against it.

Winkleblack, who previously served as CFO at H.J. Heinz, is now non-executive chair of Wendy’s board. Winkleblack has been a director since 2016.

Profitable start-up founders’ recommendation for aspiring entrepreneurs

The Junior Achievement Free Enterprise Center located in Greenwood Village, Colorado, is where high school students can explore careers and develop a plan to pursue their goals. The center aims to inspire the next generation of entrepreneurs.

Entrepreneurship is a common goal for younger people.

More than half, or 54%, of Gen Z adults say that they think they’d be happier owning their own business than working a normal day job, according to CNBC and SurveyMonkey’s new Workforce Survey. The survey polled 5,993 U.S. adults in the workforce in early April — including 770 Gen Z respondents age 27 and younger.

More from Your Money:

Here’s a look at more stories on how to manage, grow and protect your money for the years ahead.

“There’s a recipe for finding your path to purpose,” said Robin Wise, the president and CEO of Junior Achievement Rocky Mountain. “It’s seeing people do things that you might want to do. It’s knowing yourself.” 

In partnership with Junior Achievement, CNBC brought together business leaders in the Denver area to speak with students about their journey in founding a company. Here are five key pieces of advice that they shared:

‘Embrace what makes you different’ 

Mowe Haile, Founder of Sky Blue Builders, Darian Simon Cofounder of Be a Good Person, and Robin Thurston, Founder and CEO of Outside Interactive, Inc. speak with students about entrepreneurship.

Caitlin Steuben | CNBC

Darian Simon co-founded the clothing company Be a Good Person in 2015 to inspire positivity. He advises young people to “embrace what makes you different.”

Simon was diagnosed with autism and ADHD, or attention-deficit/hyperactivity disorder, at age 28. Now 30, he said he rejects the “disorder” part of the diagnosis and embraces it as his superpower.

“My greatest strengths are my neurodivergence because I have less inhibitive space in my brain, therefore I can ideate better,” he said. “Therefore the box doesn’t really exist in the same ways.”

Value adaptability

Robin Thurston sold his digital fitness technology start-up to Under Armour for $150 million in 2013. He recently founded Outside Interactive, a network of media brands in endurance sports, the outdoors and healthy living.

He compares starting a business to going on a difficult hike and advises keeping that analogy in mind as you embark on the journey — you’ll need to embrace the unknown, recognize that things are unlikely to go according to plan and work through inevitable difficulties, he said.

“That’s what great entrepreneurs do,” Thurston said. “They’re resilient, and they work their way through those challenges.” 

Recognize challenges ‘as opportunities’

Camila Uzcategui co-founded Vitro3D, a company that uses 3D printing-like technology in advanced manufacturing spaces, in 2020. She said her background in physics and interest in experimenting with technology taught her the value of failure. 

“In all of those challenges, I like to see them as opportunities to either pivot into a potentially new direction or pivot into a better way of understanding something,” Uzcategui said.

Expect excellence from your team

Mowa Haile founded Sky Blue Builders, a construction company, during the Great Recession in 2009. He said it’s important to surround yourself with people who share your passion — and always expect excellence from them.  

“When you’re an entrepreneur and you have a team, you’re there to coach them and lead them and encourage them,” he said. 

Surround yourself with the right people

Lara Merriken founded Larabar, a company that makes vegan, gluten-free, plant-based bars, in 2000 after a career in social work.

“A lot of people were literally naysayers,” she recalled. “They were just like, why would you do this? Why would you get into a category that’s oversaturated?” 

She said that identifying and working with trusted confidants who were supportive and encouraging were critical to the company’s success. She sold Larabar to General Mills in 2008 for about $55 million. 

Another recipe for success is to learn from other entrepreneurs’ stories, Merriken said. “While we have our companies, we still need inspiration every day.”

SIGN UP: Money 101 is an 8-week learning course to financial freedom, delivered weekly to your inbox.

Don’t miss these insights from CNBC PRO

Wealthy Homie Quan’s Girlfriend Breaks Her Silence On His Demise

Rich Homie Quan‘s girlfriend is breaking her silence on a moment that “traumatized” her. Amber Williams delivered her first statement about the passing of her sons’ father on Sept. 7. Quan died on Thursday, September 5, at his home. He was 34 years old.

RELATED: Rest In Peace! Here Are 5 Facts You Didn’t Know About Rich Homie Quan

Rich Homie Quan’s Girlfriend Says She Is “Heartbroken”

Amber began her statement by saying the pain of Quan’s death is “unbearable.” She followed up by showing gratitude for the outpour of love for the Atlanta rapper and the people who have reached out to her.

“I’m traumatized from a moment that’ll forever be in my head,” Amber wrote on Instagram Stories.

Hours after his family confirmed his death on Sept. 5, TMZ released the audio of Williams’ 911 call. Her voice cracked a few times as she explained how long the Atlanta rapper had been unconscious and the conditions she found him in.

In the 911 audio, Amber explained to the dispatcher that Quan had fallen asleep on the couch on Wednesday night. The next morning, she placed a blanket on him while heading out the door for school drop-off. However, when she returned, she noticed he hadn’t moved. After inspecting him closer, Williams discovered he didn’t have a heartbeat, wasn’t breathing, and had foam oozing from his mouth.

The Fulton County morgue has yet to confirm his cause of death, but people formally close to the rapper, including rapper Boosie, have fueled speculations of a drug overdose.

Amber Williams Speaks On Her 15-Year Relationship With Quan

Additionally, Amber is making it clear that she has “nothing to prove” regarding her 15-year-old ties with Rich Homie Quan. Williams and the ‘Lifestyle’ artist co-parented two sons, 10-year-old Royal Lamar and 3-year-old Layor Leonis. He has two additional children, Devin and Khosen, from previous relationships.

“I have nothing to prove because my love for my other half was ALWAYS shown, I had nothing to hide. Please respect me and the family at this time. Our house is no longer a home. I’m completely heartbroken. 15 years gone. I’ll never be the same. This is a complete nightmare. We never could let go, but you didn’t have to leave me like this,” she wrote on IG Stories.

It appears that Rich Homie Quan’s girlfriend is indirectly addressing circulating photos and videos of him looking cozy with other women. At least four women, including rapper Erica Banks, have shared that type of content since RHQ’s death.

Rich Homie Quan for the 3rd Time another lady https://t.co/0HsrDAN12p pic.twitter.com/6c7eYHoOQZ

— Markisha Marie (@ByMMarie) September 6, 2024

Internet users dragged Banks into deleting a post that showed Quan kissing her cheeks and lying on her lap. In her caption, she claimed that all he wanted was “to find happiness again.” “I’m just glad we were able to enjoy such peaceful and memorable moments while you were here,” she wrote. Erica has yet to address the backlash.

In addition to Rich Homie Quan’s girlfriend, his father has also broken his silence on the death. In an initial statement on Friday (Sept. 6), he spoke of feeling unbearable pain. Then, on Saturday (Sept. 7), he shared the now-gone plans he and Quan made last week to spend some quality time together.

RELATED: Oh Wow! Video Shows Rich Homie Quan’s Final Performance Amid His Dad Recalling One Of Their Last Talks 

What Do You Think Roomies?

Eli Lilly might develop into the primary $1 trillion healthcare inventory

A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024.

Scott Olson | Getty Images

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Earlier this month, Berkshire Hathaway topped $1 trillion in market value, the first non-tech company in the U.S. to do so. Soon, pharmaceutical giant Eli Lilly could become the first health-care company to join that club. 

Why? Eli Lilly is riding the soaring demand for its injectable weight loss drug Zepbound and diabetes medication Mounjaro, which are incretin drugs that mimic hormones produced in the gut to tamp down appetite and regulate blood sugar. Revenue from Mounjaro and Zepbound now account for almost 40% of Eli Lilly’s total sales, according to its second-quarter results in August.  

The company is one of two dominant players in the weight loss drug market, which some analysts believe could be worth $150 billion by the end of the decade. Eli Lilly may also be pulling ahead of its main rival, Novo Nordisk, as it shows progress toward expanding the supply of its drugs. 

Novo Nordisk is also investing billions to boost manufacturing. But its own weight loss and diabetes drugs, Wegovy and Ozempic, missed sales expectations for the second quarter in part due to pricing pressure in the U.S. 

Investors are also encouraged by the other possible health benefits of Eli Lilly’s treatments, which could boost their long-term revenue potential. The company has released several study results over the last year showing Zepbound’s promise as a treatment for obesity-related conditions such as obstructive sleep apnea, fatty liver disease and cardiovascular disease. 

Shares of Eli Lily have soared more than 60% this year, putting its market value at nearly $900 billion. 

And the company could reach that $1 trillion mark soon. Eli Lilly’s stock soared almost 10% on Aug. 8 following its second-quarter results that surpassed Wall Street’s expectations. The drugmaker could post another blowout quarter on Oct. 30. 

Shares could also get a boost from potential data and regulatory approvals. For example, Eli Lilly expects the Food and Drug Administration to make a decision on whether to approve Zepbound for sleep apnea by the end of the year. 

Eli Lilly could potentially release data from a late-stage trial that pits Zepbound directly against Novo Nordisk’s Wegovy by the end of the year, according to an Aug. 20 note from Leerink Partners analyst David Risinger. 

Feel free to send any tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

Latest in health-care tech: Another continuous glucose monitor hits the market

Stacey Wescott | Chicago Tribune | Tribune News Service | Getty Images

It’s raining continuous glucose monitors! 

Abbott Laboratories on Thursday announced its first over-the-counter continuous glucose monitor Lingo is available in the U.S., just days after its competitor Dexcom launched a similar product.

Continuous glucose monitors are small sensors that stick through the skin to measure real-time glucose levels. The devices have traditionally been prescribed to diabetes patients since they can help alert those users to emergencies. Lingo is more consumer friendly, as it’s meant for adults who are not taking insulin. 

Glucose is a sugar molecule that comes from food, and it’s the body’s main source of energy. Everyone’s glucose levels fluctuate, but consistently elevated levels can lead to more serious conditions like heart disease, insulin resistance and metabolic disease, Abbott said.

Lingo is designed to help users learn about how their bodies respond to food, exercise, sleep and stress, as well as how they can manage their glucose levels in healthier ways. 

The U.S. Food and Drug Administration approved Lingo in June. It’s available without a prescription, and users can buy one sensor online for $49, two sensors for $89 or six sensors for $249.

Dexcom’s new over-the-counter continuous glucose monitor is called Stelo, and the FDA approved it in March. An ongoing Stelo subscription costs $89 a month, and users can also buy a one-month supply for $99 at a time.

I tested out Stelo prior to its launch, and you can read about my experience here. I haven’t tried Lingo yet, but Abbott walked me through the app and how it works. 

One feature that stood out to me is Abbott’s “Lingo Count,” a metric designed to help users understand glucose spikes. That occurs when the amount of sugar present in the bloodstream rapidly increases and then decreases, commonly after eating. 

The Lingo Count algorithm assigns a numeric value to each glucose spike, and it’s supposed to represent how significant the impact of that fluctuation is. Users have a total target Lingo Count that they want to aim to stay below each day, and they can see their progress over time. 

In order to learn how to manage glucose spikes, Lingo users can participate in challenges and access educational materials within the app. I think the challenges could serve as a fun way to engage people around their glucose, and I’m interested to try them for myself. 

On the whole, I thought the app seemed intuitive and helpful. The data is presented in a way that doesn’t feel too complex or overwhelming, and consumers have the option to go deeper if they want.  

I’m planning to test out Lingo later this month, so I’ll have more to share soon!

Feel free to send any tips, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.

Decide Chutkan Simply Created A Nightmare For Trump

Judge Chutkan released her scheduling order on the federal Trump 1/6 trial and the case is going to be front and center through the rest of the election.

According to Andrew Weissmann, Trump didn’t get any special treatment because he is the Republican candidate for president, “Judge Chutkan treats Trump like any other defendant, and orders simultaneous briefing on three issues: immunity, statutory grounds (meaning the new S Ct Fischer decision on the obstruction statute) and on appointment of the Special Counsel. All to be done in short order, regardless of politics and the political calendar.”

Judge Chutkan said during a hearing earlier in the day

that the election would not be a factor in her decision, and it wasn’t. Chutkan isn’t going to change the hearing schedule because the defendant is running for the White House.

The conservative Supreme Court majority created a headache for Trump by holding on to the presidential immunity decision for so long. If the court had released the decision quickly, the trial would have potentially been more out of the way of the campaign. Instead, Trump’s lawyers are going to be in court and for the next two months, Trump’s legal problems and alleged role in the insurrection will be in front of the voters.

Trump’s legal problems have jumped back into the news at the worst possible time for the ex-president.

To talk to us and get more posts like this, join us on Reddit.

Jason is the managing editor. He is also a White House Press Pool and a Congressional correspondent for PoliticusUSA. Jason has a Bachelor’s Degree in Political Science. His graduate work focused on public policy, with a specialization in social reform movements.

Awards and  Professional Memberships

Member of the Society of Professional Journalists and The American Political Science Association

Jason EasleyLatest posts by Jason Easley (see all)